country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-181558

Copy Link Print Information

Anticancer agent 303

Anticancer agent 303 is a selective, orally active anticancer agent belonging to the pyrazolopyridine derivatives. Anticancer agent 303 exhibits low cytotoxicity to healthy cells, with a selective window of approximately 2-fold between cancer cells and healthy cells. Anticancer agent 303 produces detectable systemic exposure in mice following intraperitoneal or oral administration. Anticancer agent 303 effectively inhibits the proliferation of prostate cancer and breast cancer cells.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Formule: C₂₇H₃₀N₆O₂
Masse moléculaire:470.57

Stockage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (274 KB)

Anticancer agent 303 Chemical Structure

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- In Vitro
- Parmacokinetics
- In Vivo
Chemical Information
Pureté et documentation
Références
Calculators
Help & FAQs
Classifications
Bioz

Activité biologique

Description

In Vitro

Anticancer agent 303 (compound 17) (5 μM; 72 h) inhibits the viability of PC-3, MCF-7 and HUVEC cells, with mean IC₅₀ values of 4.8 μM, 3.9 μM and 8.7 μM, respectively^[1].
Anticancer agent 303 (5 μM; 1-24 h) accumulates in PC-3 cells in a time-dependent manner, reaching a level of 245.8 ng/40,000 cells (104.5% of the initial administered dose) after 24 h of treatment at 5 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay^[1]

Cell Line:

human prostate adenocarcinoma PC-3 cells
Concentration:

5 μM
Incubation Time:

72 h
Result:

Reduced PC-3 cell viability to 36% relative to DMSO control.
Exhibited an average IC₅₀ of 4.8 ± 0.9 μM.

Cell Cytotoxicity Assay^[1]

Cell Line:

human breast adenocarcinoma MCF-7 cells
Concentration:

5 μM
Incubation Time:

72 h
Result:

Reduced MCF-7 cell viability to 33% relative to DMSO control.
Exhibited an average IC₅₀ of 3.9 ± 0.9 μM.

Parmacokinetics

Species	Dose	Route	C_max	T_max	T_1/2	AUC_0-t	AUC_0-∞	Bioavailability
Mice^[1]	4 mg/kg	i.p.	372.2 ng/mL	4.8 h	14.4 h	5847.1 ng·h/mL	8721.3 ng·h/mL	/
Mice^[1]	8 mg/kg	p.o.	199.0 ng/mL	6.5 h	16.3 h	3338.0 ng·h/mL	5299.1 ng·h/mL	29.13 %

In Vivo

Anticancer agent 303 (compound 17) achieves systemic exposure in mice via intraperitoneal (i.p.) and oral (p.o.) administration. Intraperitoneal injection yields higher systemic exposure than oral administration, as indicated by increased Cmax and AUC, and has a shorter time to peak concentration (Tmax), while the elimination half-lives of the two administration routes are similar. In addition, the dose-normalized relative oral bioavailability of Anticancer agent 303 is 29.13%^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

Masse moléculaire 470.57
Formule C₂₇H₃₀N₆O₂
SMILES

O=C(NC1=CC=CC=C1)NC2=CC(OCCNC3CCCCC3)=C4C(N(C5=CC=CC=C5)N=C4)=N2
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

Please store the product under the recommended conditions in the Certificate of Analysis.

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (274 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Georgiou M, et al. Optimization of Pyrazolo[3,4‑b]pyridine Analogues: Synthesis, In Vitro Anticancer Evaluation and In Vivo Pharmacokinetics. ACS Omega. 2026;11(5):8479-8495. Published 2026 Jan 24. [Content Brief]

Calculators

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

MOQ

Minimum order quantity

100 mg

Obtenir un devis En stock

Other size

Obtenir un devis